Galmed Pharmaceuticals Stock Forecast, Price & News

-0.11 (-3.46 %)
(As of 04/16/2021 04:00 PM ET)
Today's Range
Now: $3.07
50-Day Range
MA: $3.56
52-Week Range
Now: $3.07
Volume279,103 shs
Average Volume380,599 shs
Market Capitalization$77.01 million
P/E RatioN/A
Dividend YieldN/A
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in ARREST Phase III pivotal study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity, and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; and a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol. The company was founded in 2000 and is headquartered in Tel Aviv-Yafo, Israel.
Galmed Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:GLMD
Year FoundedN/A



Sales & Book Value

Annual Sales$2.04 million
Book Value$3.30 per share


Net Income$-20,460,000.00


Market Cap$77.01 million
Next Earnings Date5/13/2021 (Estimated)


Galmed Pharmaceuticals (NASDAQ:GLMD) PT Lowered to $25.00
March 25, 2021 |
Galmed Dips 2% On Larger-Than-Expected Quarterly Loss
March 19, 2021 |
Galmed Pharmaceuticals: Q4 Earnings Snapshot
March 18, 2021 |
Galmed Hosting KOL Symposium and Pipeline Update
January 19, 2021 |
Is Galmed Pharmaceuticals Ltd (GLMD) A Good Stock To Buy?
December 4, 2020 |
Galmed Pharmaceuticals Ltd. to Host Earnings Call
November 12, 2020 |
See More Headlines


Overall MarketRank

1.46 out of 5 stars

Medical Sector

576th out of 2,021 stocks

Pharmaceutical Preparations Industry

271st out of 772 stocks

Analyst Opinion: 3.4Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
-0.11 (-3.46 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GLMD News and Ratings via Email

Sign-up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions

Is Galmed Pharmaceuticals a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Galmed Pharmaceuticals stock.
View analyst ratings for Galmed Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Galmed Pharmaceuticals?

Wall Street analysts have given Galmed Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Galmed Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Galmed Pharmaceuticals?

Galmed Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 288,300 shares, an increase of 30.2% from the March 15th total of 221,500 shares. Based on an average daily volume of 404,400 shares, the short-interest ratio is currently 0.7 days. Currently, 1.5% of the company's stock are sold short.
View Galmed Pharmaceuticals' Short Interest

When is Galmed Pharmaceuticals' next earnings date?

Galmed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Galmed Pharmaceuticals

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) announced its quarterly earnings results on Wednesday, March, 17th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.12.
View Galmed Pharmaceuticals' earnings history

How has Galmed Pharmaceuticals' stock price been impacted by Coronavirus?

Galmed Pharmaceuticals' stock was trading at $4.21 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GLMD stock has decreased by 27.1% and is now trading at $3.07.
View which stocks have been most impacted by COVID-19

What price target have analysts set for GLMD?

7 equities research analysts have issued 12 month price targets for Galmed Pharmaceuticals' stock. Their forecasts range from $8.00 to $33.00. On average, they anticipate Galmed Pharmaceuticals' stock price to reach $18.14 in the next year. This suggests a possible upside of 491.0% from the stock's current price.
View analysts' price targets for Galmed Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Galmed Pharmaceuticals' key executives?

Galmed Pharmaceuticals' management team includes the following people:
  • Mr. Allen Baharaff, Co-Founder, CEO, Pres & Director (Age 56, Pay $784.86k)
  • Mr. Yohai Stenzler, CFO & Controller (Age 38, Pay $155.34k)
  • Mr. Guy Nehemya, Chief Operating Officer (Age 36, Pay $165.43k)
  • Dr. Liat Hayardeny, Chief Scientific Officer (Age 54, Pay $242.52k)
  • Dr. Tali Gorfine, Chief Medical Officer (Age 51, Pay $242.28k)
  • Ms. Yael Hollander, VP of Legal Affairs & Strategy (Age 38)

Who are some of Galmed Pharmaceuticals' key competitors?

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP).

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galmed Pharmaceuticals' stock price today?

One share of GLMD stock can currently be purchased for approximately $3.07.

How much money does Galmed Pharmaceuticals make?

Galmed Pharmaceuticals has a market capitalization of $77.01 million and generates $2.04 million in revenue each year. The biopharmaceutical company earns $-20,460,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis.

How many employees does Galmed Pharmaceuticals have?

Galmed Pharmaceuticals employs 17 workers across the globe.

What is Galmed Pharmaceuticals' official website?

The official website for Galmed Pharmaceuticals is

Where are Galmed Pharmaceuticals' headquarters?

Galmed Pharmaceuticals is headquartered at 16 TIOMKIN STREET, TEL AVIV L3, 6578317.

How can I contact Galmed Pharmaceuticals?

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448 or via email at [email protected]

This page was last updated on 4/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.